[go: up one dir, main page]

AR056291A1 - Composiciones farmaceuticas para el tratamiento de la trombosis - Google Patents

Composiciones farmaceuticas para el tratamiento de la trombosis

Info

Publication number
AR056291A1
AR056291A1 ARP060101205A ARP060101205A AR056291A1 AR 056291 A1 AR056291 A1 AR 056291A1 AR P060101205 A ARP060101205 A AR P060101205A AR P060101205 A ARP060101205 A AR P060101205A AR 056291 A1 AR056291 A1 AR 056291A1
Authority
AR
Argentina
Prior art keywords
treatment
pharmaceutical compositions
inhibitors
antagonists
trombosis
Prior art date
Application number
ARP060101205A
Other languages
English (en)
Inventor
Paul A Reilly
James C Gilbert
Thomas H Mueller
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36423564&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR056291(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR056291A1 publication Critical patent/AR056291A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composiciones farmacéuticas que comprenden al menos un inhibidor directo de la trombina y al menos un compuesto activo adicional elegido de entre los grupos formados por inhibidores de plaquetas, heparinas de bajo peso molecular (HBPM) y heparinoides, así como heparina no fraccionada, inhibidores del factor Xa, inhibidores combinados de trombina/factor Xa, antagonistas del receptor de fibrinogeno (antagonistas de la glucoproteína IIb/IIa) y antagonistas de la vitamina K, opcionalmente junto con uno o más excipientes o vehículos farmacéuticamente aceptables para el tratamiento de la trombosis.
ARP060101205A 2005-03-29 2006-03-29 Composiciones farmaceuticas para el tratamiento de la trombosis AR056291A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05006711 2005-03-29

Publications (1)

Publication Number Publication Date
AR056291A1 true AR056291A1 (es) 2007-10-03

Family

ID=36423564

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101205A AR056291A1 (es) 2005-03-29 2006-03-29 Composiciones farmaceuticas para el tratamiento de la trombosis

Country Status (19)

Country Link
US (2) US20060222640A1 (es)
EP (1) EP1885354A2 (es)
JP (1) JP2008534552A (es)
KR (1) KR20070116936A (es)
CN (1) CN101151030A (es)
AR (1) AR056291A1 (es)
AU (1) AU2006228600A1 (es)
BR (1) BRPI0608656A2 (es)
CA (1) CA2602563A1 (es)
CL (1) CL2010000395A1 (es)
EA (1) EA015122B1 (es)
IL (1) IL186267A0 (es)
MX (1) MX2007010664A (es)
NO (1) NO20074149L (es)
NZ (1) NZ562775A (es)
TW (1) TW200722089A (es)
UA (1) UA92603C2 (es)
WO (1) WO2006103206A2 (es)
ZA (1) ZA200706698B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906894B1 (en) 2000-07-27 2014-12-09 Thomas N. Thomas Methods for preventing and treating thrombotic disorders
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
DE10339862A1 (de) * 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
IL159273A0 (en) * 2003-12-09 2004-06-01 Transpharma Medical Ltd Transdermal delivery system for sustained release of polypeptides
US20080274166A1 (en) * 2005-06-10 2008-11-06 Transpharma Medical Ltd. Patch for Transdermal Drug Delivery
WO2008009639A2 (en) * 2006-07-17 2008-01-24 Boehringer Ingelheim International Gmbh New indications for direct thrombin inhibitors
JP2010505906A (ja) * 2006-10-10 2010-02-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ３−［（２−｛［４−（ヘキシルオキシカルボニルアミノ−イミノ−メチル）−フェニルアミノ］−メチル｝−１−メチル−１ｈ−ベンゾイミダゾール−５−カルボニル）−ピリジン−２−イル−アミノ］−プロピオン酸エチルエステルの生理学的に許容される塩
DE102006051625A1 (de) 2006-11-02 2008-05-08 Bayer Materialscience Ag Kombinationstherapie substituierter Oxazolidinone
JP5508272B2 (ja) * 2007-10-29 2014-05-28 トランスファーマ メディカル リミテッド 垂直的なパッチ乾燥
US20110236405A1 (en) * 2008-07-29 2011-09-29 Tel Hashomer Medical Research Infrastructure And Services Ltd. Coagulation factor modulation for controlling transplant organ size
CA2735983A1 (en) * 2008-09-10 2010-03-18 Transpharma Medical Ltd. Transdermal delivery of oligosaccharides
PE20110431A1 (es) * 2008-11-11 2011-07-13 Boehringer Ingelheim Int Etexilato de dabigatran o una sal del mismo
MX2011004796A (es) * 2008-11-11 2011-05-30 Boehringer Ingelheim Int Metodo para tratar o prevenir la trombosis usando etexilato de diabigatran o una sal del mismio con una eficacia mejorada sobre la terapia con warfarina convencional.
EP2358367A1 (en) * 2008-11-11 2011-08-24 Boehringer Ingelheim International GmbH Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
KR20110115578A (ko) 2008-12-30 2011-10-21 트롬보로직 에이피에스 장기 부전이 발달할 증가된 위험이 있는 중증 질환 환자의 확인 방법 및 이의 치료를 위한 화합물
DK2667878T3 (en) 2011-01-25 2016-06-27 Univ Catholique Louvain Configurations and methods for cell transplantation
CN102250099B (zh) * 2011-05-16 2013-10-16 中国药科大学 一类非肽类抗凝血酶抑制剂、其制法以及医药用途
JP6034406B2 (ja) * 2012-01-25 2016-11-30 ユニヴェルシテ カソリック ド ルーヴァンＵｎｉｖｅｒｓｉｔｅ Ｃａｔｈｏｌｉｑｕｅ Ｄｅ Ｌｏｕｖａｉｎ 細胞移植のための組成物および方法
WO2014001220A1 (en) 2012-06-25 2014-01-03 Boehringer Ingelheim International Gmbh Method for prevention of stroke
EP2722034B1 (en) * 2012-10-19 2020-09-16 Sanovel Ilac Sanayi ve Ticaret A.S. Oral pharmaceutical formulations comprising dabigatran
EP2722033A1 (en) * 2012-10-19 2014-04-23 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical Compositions of Dabigatran Free Base
ES2759228T3 (es) 2013-07-05 2020-05-08 Univ Catholique Louvain Medio acondicionado de células madre de hígado de adultos y su uso en el tratamiento de trastornos del hígado
DE102014108210A1 (de) * 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
CN105250286A (zh) * 2015-11-13 2016-01-20 谭惠娟 一种抗血栓组合物
CN108236612A (zh) * 2016-12-27 2018-07-03 李志忠 用于冠脉介入手术中抗凝的组合产品及其用途
US12251377B2 (en) 2019-03-06 2025-03-18 University Of Rochester Anticoagulant compositions and uses thereof
US11654036B2 (en) 2020-05-26 2023-05-23 Elixir Medical Corporation Anticoagulant compounds and methods and devices for their use
CN115192691B (zh) * 2022-08-31 2025-03-04 晓恩医药包装材料(安庆)有限公司 一种阿加曲班注射液及预灌封注射器

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) * 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
US5510330A (en) * 1994-03-25 1996-04-23 Boehringer Mannheim Gmbh Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof.
NZ286082A (en) * 1995-03-15 1998-09-24 Behringwerke Ag Method of treating acute myocardial infarction with hirudin and acetylsalicylic acid in patients not undergoing thrombolytic treatment
FR2744918B1 (fr) * 1996-02-19 1998-05-07 Sanofi Sa Nouvelles associations de principes actifs contenant un derive de thieno(3,2-c)pyridine et un antithrombotique
PE121699A1 (es) * 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
US6414008B1 (en) * 1997-04-29 2002-07-02 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions
DE19834751A1 (de) * 1998-08-01 2000-02-03 Boehringer Ingelheim Pharma Disubstituierte bicyclische Heterocyclen, ihre Herstellung und ihre Verwendung als Arzneimittel
GB9930540D0 (en) * 1999-12-23 2000-02-16 Rhone Poulenc Rorer Pharma Chemical compounds
GB0014134D0 (en) * 2000-06-10 2000-08-02 Astrazeneca Ab Combination therapy
CN100398104C (zh) * 2001-09-14 2008-07-02 三菱制药株式会社 抗血栓药和吡唑啉酮衍生物的组合药物
NZ535663A (en) * 2002-03-07 2006-06-30 Boehringer Ingelheim Pharma Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] propionic acid ethyl ester and the salts thereof
DE10235639A1 (de) * 2002-08-02 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Prodrugs von 1-Methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carbonsäure-(N-2-pyridyl-N-2-hydroxycarbonylethyl)-amid, ihre Herstellung und ihre Verwendung als Arzneimittel
JP2006524203A (ja) * 2003-04-24 2006-10-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング トロンビンの過剰形成及び／又はトロンビンレセプターの発現上昇により生じる血栓塞栓性疾病及び疾患の治療及び予防のためのジピリダモール又はモピダモールの使用

Also Published As

Publication number Publication date
CL2010000395A1 (es) 2010-08-20
EA200701841A1 (ru) 2008-02-28
ZA200706698B (en) 2008-12-31
WO2006103206A2 (en) 2006-10-05
MX2007010664A (es) 2007-12-12
US20060222640A1 (en) 2006-10-05
EA015122B1 (ru) 2011-06-30
NO20074149L (no) 2007-12-11
IL186267A0 (en) 2008-01-20
CA2602563A1 (en) 2006-10-05
WO2006103206A3 (en) 2007-01-11
CN101151030A (zh) 2008-03-26
EP1885354A2 (en) 2008-02-13
US20100184729A1 (en) 2010-07-22
TW200722089A (en) 2007-06-16
AU2006228600A1 (en) 2006-10-05
KR20070116936A (ko) 2007-12-11
UA92603C2 (ru) 2010-11-25
JP2008534552A (ja) 2008-08-28
BRPI0608656A2 (pt) 2010-01-19
NZ562775A (en) 2011-03-31

Similar Documents

Publication Publication Date Title
AR056291A1 (es) Composiciones farmaceuticas para el tratamiento de la trombosis
CL2008003798A1 (es) Compuestos derivados de heterobiciclos aromaticos sustituidos, inhibidores de pi3 quinasa; composicion farmaceutica; utiles en el tratamiento de cancer, melanomas, glioblastomas, entre otras enfermedades.
UY28766A1 (es) Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico
UY32926A (es) Compuestos como antagonistas de los receptores de ácido lisofosfatídico
CL2008002793A1 (es) Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
CL2011003147A1 (es) Compuestos derivados de n-(1-4-(1h-pirazol-5-il)ftalazina-1-il) piperidina-4-il) benzamida; composicion farmaceutica que los contiene, utiles como antagonista de la trayectoria de hedgehog, en el tratamiento del cancer.
ECSP066882A (es) Compuestos de imidazol
DOP2010000234A (es) Antagonistas n,n-disustituidos de aminoalquilbifenilo de receptores d2 de prostaglandina
ECSP099319A (es) Analogos de tiofeno para el tratamiento o prevencion de las infecciones por flavivirus
AR071523A1 (es) Compuestos biciclicos fusionados, un proceso para su preparacion, el compuesto para ser utilizado como medicamento en el tratamiento y profilaxis de enfermedades, una composicion farmaceutica y un conjunto que comprende paquetes separados del compuesto y de un ingrediente activo del medicamento
PA8620501A1 (es) Compuestos utiles en terapia
CL2009000873A1 (es) Compuestos derivados de ciclohepta[b]piridina, antagonistas del receptor de cgrp; composicion farmaceutica; y uso para el tratamiento de la migrana.b
ECSP088103A (es) Nuevos derivados de 2-azetidinona como inhibidores de la absorción del colesterol para el tratamiento de condiciones de hiperlipidemia
GT200500225A (es) Compuestos de aminoheteroarilo enantiomericamente puros como inhibidores de proteina quinasa
CR10288A (es) Pirazoles como inhibidores de la 11-beta-hsd1
CL2008002430A1 (es) Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc.
CR10277A (es) Pirazolquinolonas como potentes inhibidores de parp
CL2011003266A1 (es) Compuestos derivados de imidazolidin-2-ona, con actividad inhibidora de 17alfa-hidroxilasa/liasa-c17,20; composicion farmaceutica que los comprende; y uso en el tratamiento de inflamacion o cancer, entre otras.
ATE469895T1 (de) Cgrp-rezeptorantagonisten
NI200900040A (es) Derivados de quinazolinona 5-substituidos como agentes antitumorales.
ECSP088358A (es) Tratamiento y profilaxis de microangiopatías
CL2008003096A1 (es) Compuestos derivados de piperidino-dihidrotienopirimidinas; inhibidores pde4; composicion farmaceutica que los comprende; y uso en el tratamiento de trastornos o enfermedades de las vias respiratorias o gastrointestinales, como tambien enfermedades inflamatorias de las articulaciones u ojos, entre otras.
GT200800198A (es) Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide del tipo 1.
ECSP078053A (es) Nuevos derivados de 2-azetidinona útiles en el tratamiento de condiciones de hiperlipidemia
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.

Legal Events

Date Code Title Description
FB Suspension of granting procedure